


WHAT IS CLAIMED IS:

1. A compound of formula I:



5 wherein,

R⁵, R^{1a} and R¹ independently are hydrogen, C₁₋₆ alkyl, halo, C₁₋₆ alkoxy, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, and trihalovinyl, said aryl optionally substituted with 1-3 groups of R^a;

10

R² is hydrogen, C₁₋₆ alkyl, and C₃₋₁₀ cycloalkyl; taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO₂, N, or NR^{2a} and optionally

15

substituted by 1-3 R^a groups;

R^{2a} is hydrogen, and C₁₋₆ alkyl;

20

R³ and R^{3a} are independently hydrogen, halo, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, and C₆₋₁₀ aryl, said aryl and alkyl optionally substituted with 1-3 groups of R^a; or

25

R³ and R^{3a} taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO₂, N, or NR^{2a} and optionally substituted by 1-3 R^a groups;

R⁴ is hydrogen, halo, C₁₋₆ alkyl, and trihaloalkyl;

30

R^a represents C₁₋₆ alkoxy, C₁₋₆ alkyl, CF₃, nitro, amino, cyano, C₁₋₆ alkylamino, or halogen; and

n represents 1-3;

or a pharmaceutically acceptable salt, enantiomer, or diastereomer thereof.

- 5 2. A compound according to claim 1 wherein R^{1a} and R¹ independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, or phenyl .
3. A compound according to claim 1 wherein R² is hydrogen or C₁₋₄ alkyl, and n is 1.
- 10 4. A compound according to claim 1 wherein R^{1a} and R¹ independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, or phenyl; R² is hydrogen or C₁₋₄ alkyl, and n is 1.
- 15 5. A compound according to claim 4 wherein R^{1a} and R¹ are tert-butyl, and R² is hydrogen.
6. A compound which is:
- 20 2-aminomethyl-5-tert-butyl-3-phenylphenol,
 2-aminomethyl-5-tert-butyl-3-(4-methylphenyl)phenol,
 3,5-di-tert-butyl-2-[(ethylamino)methyl]phenol,
 3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol,
 3,5-di-tert-butyl-2-[(methylamino)methyl]phenol,
 3,5-bis(trichlorovinyl)-2-[(ethylamino)methyl]phenol,
25 3,5-di-tert-butyl-2-[(propylamino)methyl]phenol,
 2-[(ethylamino)methyl]-5-(trichlorovinyl)phenol,
 3,5-di-tert-butyl-2-[(butylamino)methyl]phenol,
 3,5-di-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
 3,5-di-tert-butyl-2-[(hexylamino)methyl]phenol,
30 3,5-di-tert-butyl-2-[(octylamino)methyl]phenol,
 3,5-di-tert-butyl-2-[(2-hydroxyethylamino)methyl]phenol,
 tert-butyl N-(2,4-di-tert-butyl-6-hydroxybenzyl)-beta-alaninate,
 3,5-di-tert-butyl-2-[(2-dimethylaminoethylamino)methyl]phenol,
 3,5-di-tert-butyl-2-[(3-phenylpropylamino)methyl]phenol,
35 3,5-di-tert-butyl-2-[(2-phenylethylamino)methyl]phenol,


- 3,5-Di-*tert*-butyl-2-[1-(ethylamino)ethyl]phenol,
 3,5-Di-*tert*-butyl-2-[(propylamino)methyl]phenol,
 3,5-Di-*tert*-butyl-2-[[pyrazin-2-ylmethyl]amino]methyl]phenol,
 2-(aminomethyl)-3,5-di-*tert*-butylphenol hydrochloride,
 5 2-Aminomethyl-5-*tert*-butylphenol hydrochloride,
 or pharmaceutically acceptable salts thereof.

7. A composition comprising a compound of claim 1 and a pharmaceutically acceptable salt thereof.

10

8. A composition comprising a compound of claim 6 and a pharmaceutically acceptable salt thereof.

9. A method for the treatment of malaria which comprises
 15 administering to a patient in need of such treatment a compound of formula I:



wherein,

20 R⁵, R^{1a} and R¹ independently are hydrogen, C₁₋₆ alkyl, halo, C₁₋₆ alkoxy, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, and trihalovinyl, said aryl optionally substituted with 1-3 groups of R^a;

R² is hydrogen, C₁₋₆ alkyl, and C₃₋₁₀ cycloalkyl; taken together with any
 25 intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO₂, N, or NR^{2a} and optionally substituted by 1-3 R^a groups;

30 R^{2a} is hydrogen, and C₁₋₆ alkyl;